"Femtechs": studies point to "new opportunities" for investors around women's health - 09/16/2022 at 12:16

“Femtechs”: studies point to “new opportunities” for investors around women’s health – 09/16/2022 at 12:16


The “femtech” market, a contraction of “female” and “technology”, would represent 50 billion dollars in 2024, according to Frost & Sullivan.

Women’s health has

long been neglected

and a change begins. It has indeed become today a rapidly expanding ecosystem, from the digital application for monitoring the menstrual cycle to the yoga of hormones, against the backdrop of the take-off of “femtechs”. But it is also becoming a catch-all market, to the point of becoming a business like any other.

A recent report by the consulting firm McKinsey confirms that if women’s health has long been considered a “niche market” – although it concerns half of humanity – things are starting to change. , with the key, also,

“new opportunities” for investors.

The start-ups specializing in this field, born with the rise of new technologies, even have a name:

“femtech”, a contraction of “female” and “technology”.

This market would represent

50 billion dollars in 2024,

according to Frost & Sullivan.

But at the confluence of health, a very supervised sector, and well-being, with much more vague rules: special menopause clothing, fertility herbal teas, food supplements,

the field of possibilities is immense

and does not follow identical rules. Yet this is one of the problems posed by the growing interest of companies in the subject of women’s health: the

lack of scientific validation.

Thus, a medical device must meet strict standards.

Founder of the young shoot Fizimed, which has developed a perineal rehabilitation probe, Emeline Hahn had her product validated via a clinical trial. This is not the case for all of its competitors, she regrets: “Doing a clinical trial makes it possible to

prove the interest of the device and get out of the ‘gadget’ box.

But that represents big investments, which is also why not everyone does it.” “We often talk about CE marking, which indicates that a particular product meets the safety standards in force. But it is not a clinical trial, which proves its effectiveness.

This can be misleading for consumers”,

says the entrepreneur.

“A vagueness” in the European GDPR regulation

Another point of attention, specific to online apps:

the issue of confidentiality.

Because if the European GDPR regulation indeed protects the use of health data, there is “a vagueness in which service providers rush” who will sometimes prefer to speak of “well-being” data, underlines Lydia Morlet-Haïdara, Director of the Law and Health Institute of the University of Paris Cité, digital specialist. In addition, “when you download an app, you accept general conditions of use and give your consent: behind,

it all depends on what you allow.

warns Lydia Morlet-Haïdara. The importance of reading these famous “T&Cs” in detail.

However, the development of these offers comes as a more or less serious response to problems that have been left unsolved for too long. Because women have often been considered as patients with

more or less valid recriminations

by traditionally male physicians. Many studies have analyzed the issue, pointing in particular to the

historical female under-representation in clinical trials.

For Doctor Thomas Borel, director of scientific affairs for the federation of pharmaceutical companies (Leem), if there is no difference today in the desire to include men and women in clinical trials , there is “however a certain deficit in the analysis according to gender”.

A phenomenon that is not without consequences: the McKinsey report notes that women have

“twice as likely as men

to experience adverse effects after taking medication”. Excluding oncology, approximately 1% of research and innovation expenditure in health is devoted to diseases specific to women, continues McKinsey. An emblematic example of the neglect associated with the health of women,


just beginning to become a recognized condition, correctly diagnosed. It is also one of the pathologies at the bedside of which countless apps are looking.

But research remains in slow motion.

“The tree that hides the forest”

This is

The tree that hides the forest,

judge Claudine Junien, professor of genetics and member of the Academy of Medicine. “We say we’re looking after women’s health because we’re talking about endometriosis, but what about other diseases, like autoimmune diseases, where there are significant differences between gender?” she asks. Thus, “women are nine times more likely to develop lupus erythematosus than men. All drug trials should

include both male and female animals”,

pleads the doctor.

There are also cardiovascular risks for women, which remain poorly understood by the general public, deplores Professor Claire Mounier-Vehier, cardiologist, who seeks to promote better diagnosis. “If we communicate with an adapted language,

women will learn to recognize their symptoms,”

she explains. In this context, the new health offers for women “represent a step forward”, says Emeline Hahn. “But if there were to be a problem with certain products that were not clinically tested, it could harm the whole sector,” she said.

As proof, the actress and well-being guru Gwyneth Paltrow distinguished herself a few years ago with “eggs” for vagina from her Goop brand, presented for a time, without scientific validation, as a solution to regulate the cycle. menstrual. Goop was convicted in 2018 for

false advertising.


Back to top